zimeldine and Narcolepsy

zimeldine has been researched along with Narcolepsy* in 3 studies

Reviews

1 review(s) available for zimeldine and Narcolepsy

Article	Year
[Narcolepsy: electrophysiologic, biochemical, pharmacologic and immunogenetic studies]. L'union medicale du Canada, 1985, Volume: 114, Issue:12 Topics: Histocompatibility Antigens Class II; HLA-DR2 Antigen; Humans; Narcolepsy; Sleep, REM; Zimeldine	1985

Other Studies

2 other study(ies) available for zimeldine and Narcolepsy

Article	Year
Effect of L-dopa on periodic movements in sleep in narcolepsy. European neurology, 1987, Volume: 27, Issue:1 Five narcoleptic patients presenting periodic movements in sleep were investigated during treatment with L-dopa administered together with a decarboxylase inhibitor. One of these patients was also treated with gamma-hydroxybutyrate and zimelidine, and recorded at the sleep laboratory under each condition. L-dopa was effective in controlling periodic movements in sleep in all patients, but gamma-hydroxybutyrate or zimelidine were not. These results are discussed in view of a dopaminergic implication in the pathogenesis of periodic movements in sleep. Topics: Adult; Female; Humans; Levodopa; Male; Movement; Narcolepsy; Periodicity; Sleep; Sodium Oxybate; Zimeldine	1987
The effect of zimelidine, a serotonin-reuptake blocker, on cataplexy and daytime sleepiness of narcoleptic patients. Clinical neuropharmacology, 1986, Volume: 9, Issue:1 Narcolepsy is a neurological syndrome characterized by two major symptoms: excessive daytime sleepiness and cataplexy. Pharmacological and biochemical evidence support the hypothesis that dopaminergic mechanisms are involved in excessive daytime sleepiness. The pathophysiology of cataplexy and the action mechanisms of anticataplectic agents remain controversial issues. Cataplexy is usually controlled by tricyclic antidepressants, but these drugs interact with several central monoamine systems and also exert an anticholinergic effect. In the present study, zimelidine, a selective serotonin reuptake inhibitor without anticholinergic activity, was administered to 11 narcoleptic patients for 1-16 months. Cataplexy improved markedly in all patients, while no changes could be documented on excessive daytime sleepiness, either by self-report or polysomnographic nap recording. These results confirm the hypothesis that hypersomnolence and cataplexy are subject to different control mechanisms; support a serotoninergic, but not a cholinergic, theory of cataplexy; and suggest that selective serotonin reuptake inhibitors may be the treatment of choice for cataplexy. Topics: Adult; Cataplexy; Female; Humans; Male; Middle Aged; Narcolepsy; Serotonin; Serotonin Antagonists; Sleep; Zimeldine	1986

Article

Year

Effect of L-dopa on periodic movements in sleep in narcolepsy.

European neurology, 1987, Volume: 27, Issue:1

Five narcoleptic patients presenting periodic movements in sleep were investigated during treatment with L-dopa administered together with a decarboxylase inhibitor. One of these patients was also treated with gamma-hydroxybutyrate and zimelidine, and recorded at the sleep laboratory under each condition. L-dopa was effective in controlling periodic movements in sleep in all patients, but gamma-hydroxybutyrate or zimelidine were not. These results are discussed in view of a dopaminergic implication in the pathogenesis of periodic movements in sleep.

Topics: Adult; Female; Humans; Levodopa; Male; Movement; Narcolepsy; Periodicity; Sleep; Sodium Oxybate; Zimeldine

1987

The effect of zimelidine, a serotonin-reuptake blocker, on cataplexy and daytime sleepiness of narcoleptic patients.

Clinical neuropharmacology, 1986, Volume: 9, Issue:1

Narcolepsy is a neurological syndrome characterized by two major symptoms: excessive daytime sleepiness and cataplexy. Pharmacological and biochemical evidence support the hypothesis that dopaminergic mechanisms are involved in excessive daytime sleepiness. The pathophysiology of cataplexy and the action mechanisms of anticataplectic agents remain controversial issues. Cataplexy is usually controlled by tricyclic antidepressants, but these drugs interact with several central monoamine systems and also exert an anticholinergic effect. In the present study, zimelidine, a selective serotonin reuptake inhibitor without anticholinergic activity, was administered to 11 narcoleptic patients for 1-16 months. Cataplexy improved markedly in all patients, while no changes could be documented on excessive daytime sleepiness, either by self-report or polysomnographic nap recording. These results confirm the hypothesis that hypersomnolence and cataplexy are subject to different control mechanisms; support a serotoninergic, but not a cholinergic, theory of cataplexy; and suggest that selective serotonin reuptake inhibitors may be the treatment of choice for cataplexy.

Topics: Adult; Cataplexy; Female; Humans; Male; Middle Aged; Narcolepsy; Serotonin; Serotonin Antagonists; Sleep; Zimeldine

1986